News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
US FDA Staff Question Forest Laboratories, Inc., Nycomed Lung Drug
April 5, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- U.S. drug reviewers questioned the safety and effectiveness of a proposed lung drug from Forest Laboratories Inc (FRX.N) and Nycomed A/S [NYCMD.UL], documents released on Monday said.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Podcast
Pfizer Wins Metsera, Trump Strikes GLP-1 Pricing Deal, FDA Awards More Priority Vouchers
November 12, 2025
·
1 min read
·
Heather McKenzie
FDA
FDA Stalwart Pazdur Named Tidmarsh’s Replacement as CDER Director
November 11, 2025
·
1 min read
·
Heather McKenzie
Vaccines
Pesky ‘Macro Factors’—aka RFK Jr.—Come for Vaccine Pharmas’ Wallets
November 7, 2025
·
4 min read
·
Annalee Armstrong
Regulatory
Wegovy, Casgevy Among Latest FDA Priority Review Voucher Recipients
November 6, 2025
·
3 min read
·
Dan Samorodnitsky